-1366x0.jpg)
The conference officially opened on October 14 at the JW Marriott Hotel, No. 8 Do Duc Duc, Hanoi. This important event marks the professional cooperation in healthcare between the governments of Vietnam and France, attracting thousands of professors, doctors, and specialists from both domestic and international backgrounds.
Organized by the Central Obstetrics and Gynecology Hospital in collaboration with the French Obstetrics and Gynecology Association (CNGOF), the conference featured over 70 high-quality scientific presentations alongside lively discussions on the most pressing topics in obstetrics, gynecology, and reproductive support.
The presentations were divided into various sessions with diverse themes, catering to the interests of attendees. This facilitated the identification of issues and solutions, enabling doctors and specialists to find the best treatment directions in healthcare, particularly in reproductive health.
Attendees not only accessed the latest knowledge in obstetrics, gynecology, and reproductive support but also had the opportunity to meet leading experts and network with colleagues both domestically and internationally to share and update professional knowledge.
At this Vietnam-France Obstetrics and Gynecology Conference, GENTIS was honored to be the main sponsor. At the exhibition area, GENTIS's booth garnered significant interest from attending doctors and specialists in obstetrics, gynecology, and reproductive support. GENTIS introduced its most advanced genetic testing products and services, prominently featuring the GenEva 92 (NIPT IVD) test. This non-invasive prenatal screening test helps screen for syndromes related to genetic abnormalities in the fetus by analyzing cfDNA from the mother's blood starting from the 10th week of pregnancy, ensuring safety and an accuracy rate exceeding 99%.
GenEva 92: An Essential Tool in Modern Prenatal Care
GenEva 92 is recognized as a crucial instrument in modern prenatal care due to its outstanding advantages:
The process is fully automated, from sample extraction to result analysis, minimizing direct handling by technicians. This significantly reduces human error, leading to more accurate and stable results, with sensitivity and specificity proven to exceed 99%.
The GenEva 92 test employs IVD-certified reagents, from cfDNA extraction chemicals to next-generation sequencing reagents.
Its proprietary result analysis software, certified CE-IVD, ensures high accuracy. This is a significant advantage that other NIPT test packages on the market do not currently offer.
GenEva 92 provides an expanded testing solution, identifying the following abnormalities:
- Three common aneuploidy syndromes in fetuses: Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).
- Four additional syndromes: XO (Turner syndrome), XXX (Triple X syndrome), XXY (Klinefelter syndrome), and XYY (Jacobs syndrome).
- Aneuploidy across all remaining chromosomes.
- 92 microdeletion/duplication abnormalities related to common genetic syndromes, including Prader-Willi/Angelman (15q11.2), DiGeorge (22q11.2), and Cri du Chat.
Moreover, GENTIS has assembled a team of highly skilled and experienced genetic doctors and specialists, ensuring thorough consultation for expectant mothers before and after testing, along with comprehensive support policies. This demonstrates GENTIS's commitment to accompanying Vietnamese mothers on their journey to care for the health of future generations.
Through the Vietnam-France Obstetrics and Gynecology Conference, GENTIS has brought the GenEva 92 testing service closer to specialists and doctors in the obstetrics and gynecology field across the country. On October 14 and 15, 2024, GENTIS's booth welcomed hundreds of attendees interested in its products and services. Engaging games with guaranteed prizes, including the exclusive translation of "Male Infertility Through a Genetic Lens" and "Genetic Abnormalities in Male Infertility" by Dr. Trinh The Son, as well as vouchers for PRP kits and water bottles, were distributed to attendees.
The GENTIS product display received significant interest from numerous delegates and guests. Here, the questions and concerns of doctors regarding GENTIS’s genetic testing services were addressed in detail. Notably, physicians and specialists highly valued GENTIS's genetic tests in obstetrics and reproductive support.
Through its service introduction at the conference, GENTIS hopes to continue collaborating with doctors, specialists, hospitals, and clinics in delivering accurate and timely genetic testing to the Vietnamese population. With the mission to enhance the physical and intellectual well-being of Vietnamese people, GENTIS is committed to continually updating, researching, and developing genetic testing services to improve screening quality and healthcare for the community.
